An Innovative Insulin Delivery System Will Be Available to Diabetics in Israel

The international corporation Valeritas recently signed an exclusive agreement with the Israeli company Tritech Biomed, which is engaged in the import and sale of medical equipment and devices, to launch its innovative product for people with type 2 diabetes in the Israeli market. This concerns the revolutionary V-Go insulin delivery system, which is already available in many countries around the world.

According to the terms of the deal, Tritech Biomed will receive rights to promote, supply, and sell the V-Go system in Israeli diabetes clinics and directly to patients suffering from type 2 diabetes. This miniature portable device attaches to the skin like a patch and provides the delivery of a specified dose of insulin to maintain its basal level for 24 hours. The device can also deliver bolus insulin on demand, which is necessary to lower blood glucose levels after meals, Valeritas notes.

“We are pleased to collaborate with partners from Tritech Biomed, which will help provide state-of-the-art V-Go insulin delivery systems to Israeli patients with type 2 diabetes who require regular insulin administration,” says Valeritas CEO John Timberlake. “Currently, there are more than 600,000 diabetics in Israel, and we hope that our device will help them better control their blood sugar levels to avoid the development of diabetes complications.”

The company emphasized that it will retain rights to product development, obtaining regulatory approval for its use, quality control, and manufacturing in Israel, while Tritech Biomed will be responsible for sales, marketing, customer service, and distribution of the V-Go systems in the region.